New drug for pediatric psoriasis! Novarca Cosentyx first-line treatment: quick and powerful removal of skin damage, improve the quality of life!

October 31, 2020 // -- Novartis recently released data from two key international Phase 3 studies that show moderate to severe spots between the ages of 6 and 18 In children and adolescents with psoriasis, Cosentyx (Chinese product name: good, generic name: secukinumab, Skuchiyu monoanti, commonly known as "Sukin monoanti" ) provides fast, powerful skin patch removal and significantly improves quality of life.
psoriasis has a far greater impact on children than the skin and can lead to a deterioration in the quality of life, which can have a lasting impact on this vulnerable group of patients.
results, which are encouraging, show that Cosentyx rapidly reduces the burden of symptoms with good safety in this vulnerable patient group, which will provide a much-needed treatment option for the pediatric patient population.
early August, Cosentyx received EU approval to treat children and adolescents with moderate to severe plaque psoriasis between the ages of 6 and 18.
drug use, the recommended dose for children weighing <50 kg is 75 mg (no lower weight limit) and for children weighing ≥50 kg is 150 mg (starting at 150 mg, which can be increased to 300 mg if required).
U.S. regulatory aspects, Cosentyx's applications for patients of the same age group have been accepted by the FDA.
children with psoriasis had a worse quality of life than their peers because of symptoms such as itching and fatigue.
these in turn can affect their emotional health and school performance.
with the EU approval, Cosentyx will provide a first-line system therapy for children with psoriasis in Europe.
, Cosentyx has been approved for four adaptations, and Novartic plans to expand to 10 over the next decade.
's two Phase III international studies of children and adolescents ages 6-18 included an open label, two-arm, parallel group, multi-center moderate to severe plaque psoriasis study, and a randomized, double-blind, placebo, and etanercept-controlled study of severe plaque psoriasis.
study, Cosentyx's dosing program was strated by weight.
studies have shown that both low-dose (75-150 mg) and high-dose (75-300 mg) Cosentyx are very effective in rapidly improving skin symptoms and quality of life and are safe for up to 52 weeks.
In children with moderate to severe plaque-type psoriasis, low-dose Cosentyx has a rapid and powerful skin plaque removal effect: 93% of patients achieved PASI 75 remission in week 12 of treatment (psoriasis area and severity index improved by 75% relative to baseline), and 69% of patients achieved PASI 75 remission in week 12 Reaching PASI 90 remission (90%) and 88% of patients reaching PASI 90 remission at week 24, in addition, 59.5% of patients achieving complete removal of deral damage at week 12 (PASI 100) and 67% reaching PASI 100 remission at week 24.
in patients with severe psoriasis, the low dose of Cosentyx ensured continuous dermising removal until week 52, with 75% of patients reaching PASI 90 remission.
severe psoriasis showed differences in PASI 75 as early as week 4 and moderate to severe psoriasis as early as week 2.
half of children with moderate to severe plaque psoriasis had been completely relieved of the symptom burden of psoriasis by 12 weeks ago, according to the Children's Quality of Life Index (CDLQI) 0/1 response.
in children with severe plaque-type psoriasis treated with low doses of Cosentyx, 44.7% of patients were fully remissioned at week 12 and 60.6% at week 52.
and high doses of Cosentyx safety characteristics are similar and consistent with established adult psoriasis adaptations.
no new safety signals were observed in children.
psoriasis is a lifelong systemic inflammatory disease that seriously affects the physical and emotional quality of life of patients.
third of all cases of psoriasis begin in childhood, with the most common onset occurring during adolescence.
severe psoriasis affects more than 350,000 children worldwide and can have a "more far-reaching" effect on children, and the physical and psychological burden of psoriasis disrupts important growth.
between 1970 and 2000, the incidence of psoriasis in children in the United States more than doubled, and the incidence of psoriasis has increased in several countries.
only a few approved treatment options are available, and unsealed medical needs remain high.
Cosentyx is the first human monoclonal antibody drug specific to target the suppression of white melebin-17A (IL-17A), which selectively targets the activity of blocking the circulation of IL-17A, reducing immune system activity and improving disease symptoms.
study revealed that IL-17A played an important role in driving the body's immune response to a variety of autoimmune diseases, including psoriasis arthritis (PsA), plaque psoriasis (PsO), strong straight spina blineitis (AS), radiologically negative mid-axis spinal arthritis (nr-axSpA).
Cosentyx was approved for listing in January 2015 and has now been approved for four adaptations (PsO, PsA, AS, nr-axSpA).
Cosentyx has strong clinical evidence, including five years of data from the top three adaptations (PsO, PsA, AS) and data from real-world evidence.
data reinforce Cosentyx's unique position as a rapid and long-lasting comprehensive treatment across axSpA, PsA, and psoriasis diseases.
, more than 340,000 patients worldwide have been treated with Cosentyx.
in China, Cosentyx ® was approved by the National Drug Administration (NMPA) at the end of April for routine treatment of adult patients with severe spina blinitis (AS).
It's good® the second adaptive disease approved in China after it was approved in March 2019 for the treatment of moderate to severe plaque psoriasis (PsO) and the first and only white melebin inhibitor approved for the treatment of severe spina brysitis (AS).
in mid-June, Cosentyx ®® was approved in China.
As an upgraded version of the pre-charged injection needle®, the ®self-feeling pen® will optimize the original method of administration in all directions, "one-touch" operation to reduce the difficulty of injection, improve the patient's treatment experience, while effectively avoiding the waste of drugs caused by operational errors, for China's guangda medium and severe plaque psoriasis patients and patients with strong spina brystitis to bring more convenient, safe and efficient treatment experience.
() Original source: Novartis presents latest Phase III data ® >® as a first-line systemic treatment in pediatric psoriasis<!--/ewebeditor:page->